Rivastigmine MD has a lower application frequency than the once-daily Rivastigmine patches generally available in the market, enabling it to improve patients’ medication adherence.

Among users of antidementia drugs, persons using memantine have the highest risk of pneumonia, new research shows. The use of rivastigmine patches is associated with an increased risk as well, say ...

However, persons using memantine or rivastigmine patches had a 1.6 and 1.15 times higher risk of pneumonia, respectively, but no elevated risk was observed among patients using rivastigmine in ...

The rivastigmine patch is already approved at doses of 4.6 mg/24 hours and 9.5 mg/24 hours for the treatment of mild to moderate dementia of the Alzheimer's disease (AD) type, ...

Rivastigmine Transdermal System is available as 4.6mg/24hrs, 9.5mg/24hrs, and 13.3mg/24hrs strengths. For more information call (973) 796-3400 or visit Alvogen.com . Picked For You ...